Physostigmine: Primary Clinical Uses
Physostigmine is primarily used as an antidote to reverse severe anticholinergic toxicity, particularly when patients develop life-threatening delirium that may require intubation for airway protection. 1
Mechanism of Action
Physostigmine is a reversible anticholinesterase inhibitor that crosses the blood-brain barrier (unlike quaternary amines like neostigmine), allowing it to reverse both central and peripheral anticholinergic effects 1. It works by:
- Inhibiting acetylcholinesterase, thereby increasing acetylcholine concentrations at cholinergic synapses
- Reversing the anticholinergic syndrome within minutes of IV administration
- Providing effects lasting approximately 45-60 minutes 1
Primary Indication: Anticholinergic Toxicity
Central Anticholinergic Syndrome
The drug reverses central toxic effects including 1:
- Anxiety, delirium, disorientation
- Hallucinations and hyperactivity
- Seizures
- Severe cases: coma and medullary paralysis
Peripheral Anticholinergic Effects
Physostigmine also reverses peripheral toxicity 1:
- Tachycardia
- Hyperpyrexia and mydriasis
- Urinary retention
- Decreased GI motility
- Reduced secretions (salivary, sweat, respiratory)
Common Causative Agents
Anticholinergic toxicity requiring physostigmine treatment results from 1:
- Belladonna alkaloids (atropine and derivatives)
- Tricyclic antidepressants
- Phenothiazines
- Antihistamines (e.g., diphenhydramine overdose) 2
- Second-generation antipsychotics like olanzapine 3
Clinical Evidence for Safety and Efficacy
Recent comprehensive safety data from 2,299 patients demonstrates that physostigmine is remarkably safe when used appropriately, with adverse effects occurring in only 18.1% of cases 4. The most common adverse effects were minor:
- Hypersalivation (9.0%)
- Nausea/vomiting (4.2%)
- Self-limited seizures (0.61%)
- Symptomatic bradycardia (0.35%)
Importantly, only 0.22% mortality was reported, and physostigmine proved safer in anticholinergic overdoses (7.7% adverse effects) compared to non-anticholinergic agents (20.6%) 4.
Hospital Stocking Requirements
Expert consensus guidelines recommend hospitals stock 4 mg of physostigmine for 8-hour emergency care coverage 5, reflecting its critical role as an emergency antidote.
Absolute Contraindications
Physostigmine must NOT be used in patients with 1:
- Asthma
- Cardiovascular disease
- Mechanical GI or urogenital obstruction
- Gangrene or diabetes
- Concurrent use with depolarizing neuromuscular blockers (succinylcholine, decamethonium)
- QRS prolongation on EKG (critical in TCA overdoses) 4
Key Safety Caveat
Avoid physostigmine in tricyclic antidepressant overdoses with QRS widening, as this was the source of historical cardiac arrests that led to underutilization of this otherwise safe antidote 4. Exercise caution in patients with coronary artery disease 4.
Secondary and Emerging Uses
While anticholinergic toxicity reversal remains the primary indication, research has identified additional applications 6:
- Post-anesthesia central anticholinergic syndrome
- Differential diagnosis of coma of unknown origin
- Restoration of vigilance after prolonged sedation
- Alcohol delirium and withdrawal syndromes
- Potential neuroprotection against hypoxic brain damage
Clinical Bottom Line
Physostigmine is significantly underutilized despite strong evidence supporting its safety and efficacy 2, 7. When severe anticholinergic delirium threatens airway protection, physostigmine can prevent intubation and ICU admission, provided contraindications (especially QRS prolongation) are excluded 2, 3.